Profund Advisors’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Profund Advisors’s Portfolio NAVB Stock Details NAVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-516	Closed	-$16K	–	1543
2015 Q1	$16K	Buy	+516	New	+$17.5K	﹤0.01%	1523
2014 Q3	–	Sell	-971	Closed	-$29K	–	1506
2014 Q2	$29K	Buy	971 +281	+41%	+$9.09K	﹤0.01%	1555
2014 Q1	$26K	Buy	+690	New	+$26.2K	﹤0.01%	1599

Other funds holding NAVB

Platinum Management New York $16.4M AUM 30.38% 1-Year Est. Return

Commerzbank Aktiengesellschaft Frankfurt, Germany $4.78B AUM 25.31% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Profund Advisors's NAVB Position: Q2 2015 in Review

Profund Advisors sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q2 2015, closing a stake of 516 shares — an estimated $16K sold.

Profund Advisors first reported a position in NAVB in Q1 2014 and held it in 3 quarters. The position peaked at $29K in Q2 2014. 79 funds tracked by Wall St. Rank hold NAVB as of Q2 2015.

Profund Advisors reported no remaining Navidea Biopharmaceuticals Inc. position as of Q2 2015 after selling out during the quarter.
Profund Advisors sold 516 Navidea Biopharmaceuticals Inc. shares in Q2 2015, an estimated $16K.
Profund Advisors first reported a position in Navidea Biopharmaceuticals Inc. in Q1 2014 and held it in 3 quarters.
Profund Advisors's Navidea Biopharmaceuticals Inc. position peaked at $29K in Q2 2014.
79 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q2 2015.

Based on Profund Advisors's 13F filing for Q2 2015, filed 11 Aug 2015.